Case 5:23-cv-06360-EJD Document 65 Filed 06/18/24 Page 1 of 28
`
`EDWARD R. REINES (Bar No. 135960)
`edward.reines@weil.com
`DEREK C. WALTER (Bar No. 246322)
`derek.walter@weil.com
`WEIL, GOTSHAL & MANGES LLP
`Silicon Valley Office
`201 Redwood Shores Parkway
`Redwood Shores, CA 94065
`Telephone: (650) 802-3000
`Facsimile: (650) 802-3100
`
`JACK NOLAN (admitted pro hac vice)
`jack.nolan@weil.com
`WEIL, GOTSHAL & MANGES LLP
`New York Office
`767 Fifth Avenue
`New York, NY 10153
`Telephone: (212) 310-8000
`Facsimile: (212) 310-8007
`
`Attorneys for Defendant and Counter-
`Plaintiff
`BIO-RAD LABORATORIES, INC.,
`
`WILSON SONSINI GOODRICH & ROSATI, P.C.
`AMY H. CANDIDO, State Bar No. 237829
`(candido@wsgr.com)
`SACHLI BALAZADEH-NAYERI, State Bar No.
`341885
`(snayeri@wsgr.com)
`One Market Plaza
`Spear Tower, Suite 3300
`San Francisco, CA 94105-1126
`Telephone: (415) 941-2000
`ERIC P. TUTTLE, State Bar No. 248440
`(eric.tuttle@wsgr.com)
`701 Fifth Avenue, Suite 5100
`Seattle, WA 98104-7036
`Telephone: (206) 883-2500
`ARIEL C. GREEN ANABA, State Bar No. 304780
`(aanaba@wsgr.com)
`633 West Fifth Street, Suite 1550
`Los Angeles, CA 90071
`Telephone: (323) 210-2900
`LISA D. ZANG, State Bar No. 294493
`(lzang@wsgr.com)
`1900 Avenue of the Stars, 28th Floor
`Century City, CA 90067
`Telephone: (424) 446-6900
`Attorneys for Plaintiff and Counter-Defendant
`CHROMACODE, INC.
`(Additional counsel listed on following page)
`UNITED STATES DISTRICT COURT
`NORTHERN DISTRICT OF CALIFORNIA
`SAN JOSE DIVISION
`
`CHROMACODE, INC., and CALIFORNIA
`INSTITUTE OF TECHNOLOGY,
`
` Case No.: 5:23-cv-06360-EJD
`
`Plaintiffs and Counter-
`Defendants,
`
`JOINT CLAIM CONSTRUCTION
`STATEMENT
`
`vs.
`
`Judge Edward J. Davila
`
`BIO-RAD LABORATORIES, INC.,
`
`Defendant and Counter-
`Plaintiff.
`
`JOINT CLAIM CONSTRUCTION STATEMENT
`
`CASE NO. 5:23-CV-06360-EJD
`
`BIO-RAD EX.1003.001
`
`1 2
`
`
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`

`

`Case 5:23-cv-06360-EJD Document 65 Filed 06/18/24 Page 2 of 28
`
`CHRISTOPHER D. MAYS, State Bar No. 266510
`(cmays@wsgr.com)
`650 Page Mill Road
`Palo Alto, CA 94304
`Telephone: (650) 493-9300
`Facsimile: (650) 565-5100
`
`Attorneys for Plaintiff and Counter-Defendant
`CHROMACODE, INC.
`
`SHEPPARD, MULLIN, RICHTER & HAMPTON,
`LLP
`MARTIN R. BADER, SBN 222865
`(mbader@sheppardmullin.com)
`JESSE A. SALEN, SBN 292043
`(jsalen@sheppardmullin.com)
`12275 El Camino Real, Suite 100
`San Diego, California 92130-4092
`Telephone: 858.720.8900
`Facsimile: 858.509.3691
`
`DARREN M. FRANKLIN, SBN 210939
`(dfranklin@sheppardmullin.com)
`333 South Hope Street, 43rd Floor
`Los Angeles, California 90071-1422
`Telephone: 213.620.1780
`Facsimile: 213.620.1398
`
`BRADLEY C. GRAVELINE, pro hac vice
`(bgraveline@sheppardmullin.com)
`321 North Clark St., 32nd Floor
`Chicago, Illinois 60654
`Telephone: 312.499.6300
`Facsimile: 312.499.6301
`
`Attorneys for Plaintiffs and Counter-Defendants
`CHROMACODE, INC. AND CALIFORNIA
`INSTITUTE OF TECHNOLOGY
`
`1 2
`
`
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`JOINT CLAIM CONSTRUCTION STATEMENT
`
`2
`
`CASE NO. 5:23 CV 04823-EJD
`
`BIO-RAD EX.1003.002
`
`

`

`Case 5:23-cv-06360-EJD Document 65 Filed 06/18/24 Page 3 of 28
`
`Pursuant to Patent Local Rule 4-3, the Patent Scheduling Order, Dkt. No. 47, the Joint
`Stipulation and Order re Filing of Second Amended Complaint and Amended Case Schedule, Dkt.
`No. 53, and the Order to Amend Patent Scheduling Order, Dkt. No. 62, Defendant and Counter-
`Plaintiff Bio-Rad Laboratories, Inc. (“Bio-Rad”) and Plaintiffs and Counter-Defendants
`ChromaCode, Inc. (“ChromaCode”), California Institute of Technology (“Caltech” and collectively
`with ChromaCode, “Plaintiffs”), by and through the undersigned counsel, hereby file their Joint
`Claim Construction Statement. Attached as Exhibits A, B and C hereto are copies of U.S. Patent
`Nos. 10,068,051 (the “’051 Patent”), 10,770,170 (the “’170 Patent”), and 11,827,921 (the “’921
`Patent” and collectively with the ’051 Patent and the ’170 Patent, the “Asserted Patents”).
`
`I.
`
`PATENT LOCAL RULE 4-3(A)
`The parties agree upon the construction of the following terms:
`None.
`
`II.
`
`PATENT LOCAL RULES 4-3(B)-(C)
`Pursuant to the Court’s standing order requiring that the parties submit no more than ten
`claim terms for construction, the following ten terms below are the key terms in dispute that are
`most likely to be case dispositive1:
`
`1 The parties reserve the right to rely on the evidence cited by the other party and additional
`portions of the intrinsic record. Additionally, to the extent the parties cite figures from the patents,
`they reserve the right to rely on corresponding passages from the specification discussing those
`figures, and vice versa.
`
`JOINT CLAIM CONSTRUCTION STATEMENT
`
`3
`
`CASE NO. 5:23-CV-06360-EJD
`
`BIO-RAD EX.1003.003
`
`1 2
`
`
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`

`

`Case 5:23-cv-06360-EJD Document 65 Filed 06/18/24 Page 4 of 28
`
`Claim Terms
`
`Bio-Rad’s Proposed
`Construction and Evidence in
`Support
`
`Plaintiffs’ Proposed
`Construction and Evidence in
`Support2
`
`“corresponds to the
`presence of a unique
`combination of presence
`or absence of said at
`least five polynucleotide
`analytes in said sample”
`
`’170 Patent Claim 1.
`
`Proposed Construction:
`
`Indefinite
`
`Supporting Evidence:
`
`See e.g., ’170 Patent Claim 1.
`
`See e.g., ’170 Patent Figs. 1-8.
`
`See e.g., ’170 Patent Abstract.
`
`See e.g., ’170 Patent at:
`1:47-3:2; 3:37-7:39; 7:51-8:24;
`8:59-9:58; 10:8-11:45; 11:47-
`23:30; 26:45-35:9; 35:11-36:42;
`36:57-37:3; 40:23-44:67; 45:8-
`49:5; 49:16-65:28.
`
`See e.g., ’170 Patent File History
` May 23, 2018 Applicant
`Arguments/Remarks
`Made in Amendment at
`5-8
`January 21, 2019
`Applicant
`Arguments/Remarks
`Made in Amendment at
`5-8
`
`
`
`Proposed Construction:3
`Not indefinite, plain and
`ordinary meaning
`Supporting Evidence:
`’051 Patent
`1:46-60; 2:4-18; 3:37-44; 3:51-
`67; 4:1-16; 4:18-5:4; 5:5-19;
`5:20-35; 5:36-60; 5:61-6:13;
`6:14-39; 6:39-47; 6:59-67; 7:12-
`23; 8:59-67; 9:43-56; 11:13-44;
`14:29-44; 17:61-18:15; 18:16-
`33;
`18:34-42;
`18:43-19:4;
`19:18-34; 19:35-50; 19:64-20:9;
`20:10-21; 20:21-50; 20:51-61;
`20:62-21:7; 21:8-54; 22:66-
`23:6; 23:40-58; 25:1-30; 29:15-
`26;
`28:47-29:11;
`32:19-27;
`32:28-36; 35:1-23; 38:23-32;
`41:10-42; 41:52-67; 56:38-52;
`Tables 1-8
`
`’170 Patent
`Specification passages
`corresponding to ’051 passages
`cited above
`Claims 1, 20
`’921 Patent
`Specification passages
`corresponding to ’051 passages
`cited above
`
`2 The ’051, ’170, and ’921 Patents are continuations of one another and share the same
`specification. For the sake of convenience, Plaintiffs have cited to the specification and figures
`for the ’051 and incorporate by reference the corresponding passages and figures from the ’170
`and ’921 Patents. Plaintiffs reserve the right to rely on equivalent passages and figures from any
`of the three Patents-in-Suit.
`3 ChromaCode notes that this term was not on the parties’ June 11, 2024, agreed upon list of ten
`terms for construction. On June 17 (the day before this Joint Claim Construction Statement was
`due), Bio-Rad unilaterally changed the list to include this term. ChromaCode reserves the right to
`raise this with the Court at an appropriate time. Bio-Rad notes this term was included
`substantially in Bio-Rad’s disclosure of 20 terms for construction as well as being disclosed as
`indefinite in Bio-Rad’s invalidity contentions. Bio-Rad served initial supporting evidence for this
`term on June 6, as did Plaintiffs. Plaintiffs have not been prejudiced by this addition.
`4
`
`JOINT CLAIM CONSTRUCTION STATEMENT
`
`CASE NO. 5:23 CV 04823-EJD
`
`1 2
`
`
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`BIO-RAD EX.1003.004
`
`

`

`Case 5:23-cv-06360-EJD Document 65 Filed 06/18/24 Page 5 of 28
`
`Claim Terms
`
`Bio-Rad’s Proposed
`Construction and Evidence in
`Support
`
`Plaintiffs’ Proposed
`Construction and Evidence in
`Support2
`
`Claims 4, 13, 14
`
`Shared Figures
`Figures 1-8
`
`’051 File History
` Aug. 5, 2014, Application
` Nov. 14, 2014, Preliminary
`Amendment
` May 12, 2016, Restriction
`Requirement
` November 3, 2016,
`Response to Restriction
`Requirement
` November 23, 2016, Office
`Action
` May 2, 2017, Response to
`Office Action
`June 6, 2017, Office Action
`
` Aug. 11, 2017 Office
`Action Response
` Aug. 23, 2017 Office
`Action
` September 22, 2017,
`Examiner Interview
`Summary
` Oct. 20, 2017, Examiner
`Interview Summary
` Nov. 6, 2017, Request for
`Continued Examination
` November 24, 2017,
`Examiner Interview
`Summary
`Jun 14, 2018, Notice of
`Allowance
`July 3, 2018, Amendment
`after allowance
`’170 File History
` March 7, 2018 Application
` March 22, 2018
`Preliminary Amendment
` March 8, 2019, Office
`Action
` May 23, 2019, Response to
`Office Action
`July 22, 2019, Office
`Action
`January 21, 2020 Request
`for Continued Examination
`
`
`
`
`
`
`
`
`
`JOINT CLAIM CONSTRUCTION STATEMENT
`
`5
`
`CASE NO. 5:23 CV 04823-EJD
`
`BIO-RAD EX.1003.005
`
`1 2
`
`
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`

`

`Case 5:23-cv-06360-EJD Document 65 Filed 06/18/24 Page 6 of 28
`
`Claim Terms
`
`Bio-Rad’s Proposed
`Construction and Evidence in
`Support
`
`
`
`
`
`Plaintiffs’ Proposed
`Construction and Evidence in
`Support2
` May 4, 2020, Notice of
`Allowance
`July 23, 2020 Amendment
`after Notice of Allowance
`July 29, 2020 Response to
`Amendment
`’921 File History
` May 1, 2020, Application
` December 16, 2020,
`Preliminary Amendment
` March 25, 2021,
`Information Disclosure
`Statement (and associated
`references)
` December 28, 2022 Office
`Action
` March 28, 2023 Response
`to Office Action
` May 10, 2023, Office
`Action
`July 10, 2023, Response to
`
`Office Action
` August 10, 2023, Notice of
`Allowance
` October 10, 2023,
`Amendment after Notice of
`Allowance
` October 23, 2023 Notice of
`Allowance
`Extrinsic evidence: Bio-Rad’s
`Patent L.R. 4-2 Disclosure of
`Preliminary Constructions and
`Evidence
`
`“providing a sample
`solution volume . .
`. comprising at least
`seven hybridization
`probes” and “contacting
`. . .”
`
`’051 Patent Claim 1.
`
`Proposed Construction:
`
`Indefinite
`
`Supporting Evidence:
`
`See e.g., ’051 Patent Claims 1, 3.
`
`See e.g., ’051 Patent Figs. 1-8.
`
`See e.g., ’051 Patent Abstract.
`
`See e.g., ’051 Patent at:
`
`Proposed Construction:
`Not indefinite; plain and
`ordinary meaning
`Supporting Evidence:
`’051 Patent
`Abstract; 1:46-54; 2:33-45;
`3:52-67; 4:17-42; 4:66-5:4;
`5:20-6:47; 6:59-67; 7:12-37;
`7:62-8:10; 8:40-57; 9:15-27;
`10:26-50; 11:13-63; 12:17-28;
`18:43-19:17; 21:54-22:65;
`28:47-29:11; 29:27-47; 33:32-
`
`JOINT CLAIM CONSTRUCTION STATEMENT
`
`6
`
`CASE NO. 5:23 CV 04823-EJD
`
`BIO-RAD EX.1003.006
`
`1 2
`
`
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`

`

`Case 5:23-cv-06360-EJD Document 65 Filed 06/18/24 Page 7 of 28
`
`Claim Terms
`
`Bio-Rad’s Proposed
`Construction and Evidence in
`Support
`1:30-42; 1:46-54; 2:33-45; 3:17-
`20; 3:52-67; 4:17-7:23; 7:49-
`8:23; 8:58-9:42; 10:26-50;
`11:13-44; 11:48-25:30; 25:34-
`44; 27:49-28:17; 28:47-29:11;
`29:15-47; 32:19-56; 33:32-
`36:21; 37:1-15; 38:48-61; 40:9-
`41:6; 42:30-47:45; 47:53-52:24;
`52:31-67:67.
`
`Plaintiffs’ Proposed
`Construction and Evidence in
`Support2
`36:29; 37:1-38:37; 47:30-
`45:49; 40:23-41:6; 41:52-
`47:30; 52:8-24; 52:50-56:20;
`56:24-37; 56:53-69:7; Claims
`1-4; Plaintiffs also incorporate
`all passim references to
`“solutions” and “probes” in the
`patents’ shared specification.
`
`’170 Patent
`Specification passages
`corresponding to ’051 passages
`cited above
`
`Claims 1, 2, 3, 4, 5, 9
`
`’921 Patent
`
`Specification passages
`corresponding to ’051 passages
`cited above
`
`Claims 1, 5, 6, 7, 14, 16, 18
`
`Shared Figures
`
`2-3, 6-7
`
`’051 File History
` Aug. 5, 2014, Application
` Nov. 14, 2014, Preliminary
`Amendment
` May 12, 2016, Restriction
`Requirement
` November 3, 2016,
`Response to Restriction
`Requirement
` November 23, 2016, Office
`Action
` May 2, 2017, Response to
`Office Action
`June 6, 2017, Office Action
`
` Aug. 11, 2017 Office
`Action Response
` Aug. 23, 2017 Office
`Action
` September 22, 2017,
`Examiner Interview
`Summary
`
`1 2
`
`
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`JOINT CLAIM CONSTRUCTION STATEMENT
`
`7
`
`CASE NO. 5:23 CV 04823-EJD
`
`BIO-RAD EX.1003.007
`
`

`

`Case 5:23-cv-06360-EJD Document 65 Filed 06/18/24 Page 8 of 28
`
`
`
`
`
`
`
`Plaintiffs’ Proposed
`Construction and Evidence in
`Support2
` Oct. 20, 2017, Examiner
`Interview Summary
` Nov. 6, 2017, Request for
`Continued Examination
` November 24, 2017,
`Examiner Interview
`Summary
`Jun 14, 2018, Notice of
`Allowance
`July 3, 2018, Amendment
`after allowance
`’170 File History
` March 7, 2018 Application
` March 22, 2018
`Preliminary Amendment
` March 8, 2019, Office
`Action
` May 23, 2019, Response to
`Office Action
`July 22, 2019, Office
`Action
`January 21, 2020 Request
`
`for Continued Examination
` May 4, 2020, Notice of
`Allowance
`July 23, 2020 Amendment
`after Notice of Allowance
`July 29, 2020 Response to
`Amendment
`’921 File History
` May 1, 2020, Application
` December 16, 2020,
`Preliminary Amendment
` March 25, 2021,
`Information Disclosure
`Statement (and associated
`references)
` December 28, 2022 Office
`Action
` March 28, 2023 Response to
`Office Action
` May 10, 2023, Office Action
`July 10, 2023, Response to
`
`Office Action
` August 10, 2023, Notice of
`Allowance
`
`
`
`
`
`Claim Terms
`
`Bio-Rad’s Proposed
`Construction and Evidence in
`Support
`
`1 2
`
`
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`JOINT CLAIM CONSTRUCTION STATEMENT
`
`8
`
`CASE NO. 5:23 CV 04823-EJD
`
`BIO-RAD EX.1003.008
`
`

`

`Case 5:23-cv-06360-EJD Document 65 Filed 06/18/24 Page 9 of 28
`
`Claim Terms
`
`Bio-Rad’s Proposed
`Construction and Evidence in
`Support
`
`Plaintiffs’ Proposed
`Construction and Evidence in
`Support2
`2023,
`10,
` October
`Amendment after Notice of
`Allowance
` October 23, 2023 Notice of
`Allowance
`
`“non-degenerately,”
`“degenerate” or
`“degeneracy”
`
`’051 Patent Claim 1.
`
`’921 Patent Claims 4,
`13, 14.
`
`Proposed Construction:
`
`Proposed Construction:
`
`“degenerate” or “degeneracy”
`means a situation where a
`legitimate result is not definitive,
`because it can indicate more than
`one possibility in terms of the
`presence or absence of an
`analyte.
`
`Supporting Evidence:
`
`See e.g., ’051 Patent Claim 1.
`See e.g., ’051 Patent Figs. 1-5, 7,
`8
`See e.g., ’051 Patent Abstract.
`See e.g., ’051 Patent at:
`1:46-2:21; 3:35-7:37; 7:49-8:18;
`8:20-23; 8:58-9:14; 9:34-
`56;11:35-45; 17:60-19:50;
`19:64-25:19; 29:15-26; 32:19-
`36; 41:10-67; 42:30-47:45;
`47:53-52:24; 52:31-67:67.
`See e.g., ’051 Patent File History
` May 2, 2017 Applicant
`Arguments/Remarks
`Made in Amendment at
`8-11
` August 11, 2017
`Response After Final
`Action at 16-20
` November 6, 2017
`Applicant
`Arguments/Remarks
`
`Plain and ordinary meaning
`
`Supporting Evidence:
`
`’051 Patent
`1:46-60; 2:4-18; 3:37-44; 3:51-
`67; 4:1-16; 4:18-42; 4:43-65;
`5:5-19; 5:20-35; 5:36-60; 5:61-
`6:13; 6:14-39; 6:39-47; 6:59-
`67; 7:12-23; 9:43-56; 11:13-44;
`14:29-44; 17:24-38, 17:61-
`18:15; 18:16-33; 18:34-42;
`18:67-19:4; 19:18-34; 19:35-
`50; 19:64-20:9; 20:10-21;
`20:21-50; 20:51-61; 20:62-
`21:7; 21:8-54; 22:66-23:6;
`23:40-58; 29:15-26; 28:47-
`29:11; 32:19-27; 32:28-36;
`41:10-42; 41:52-67, 51:45-50;
`Tables 1-8; Plaintiffs also
`incorporate all passim
`references to “degenerate,”
`“degeneracy,” and “non-
`degenerate” in the patents’
`shared specification.
`
`’170 Patent
`Specification passages
`corresponding to ’051 passages
`cited above
`Claim 1
`
`’921 Patent
`
`Specification citations
`corresponding to ’051 passages
`cited above
`Claims 1, 4, 13, 14
`
`1 2
`
`
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`JOINT CLAIM CONSTRUCTION STATEMENT
`
`9
`
`CASE NO. 5:23 CV 04823-EJD
`
`BIO-RAD EX.1003.009
`
`

`

`Case 5:23-cv-06360-EJD Document 65 Filed 06/18/24 Page 10 of 28
`
`Plaintiffs’ Proposed
`Construction and Evidence in
`Support2
`Shared Figures
`Figures 1, 2, 3, 5, 7, 8
`
`Claim Terms
`
`Bio-Rad’s Proposed
`Construction and Evidence in
`Support
`Made in Amendment at
`11-12
`See e.g., ’921 Patent Claim 1.
`See e.g., ’921 Patent Figs. 1-5, 7,
`8
`See e.g., ’921 Patent Abstract.
`See e.g., ’921 Patent at:
`1:51-2:26; 3:56-7:44; 7:55-8:23;
`8:25-28; 8:63-9:19; 9:39-61;
`11:39-51; 16:46-18:25; 18:39-
`23:67; 27:51-62; 30:55-31:5;
`39:43-40:28; 40:56-45:42;
`45:49-50:19; 50:27-67:5.
`See e.g., ’921 Patent File History
` March 23, 2023
`Applicant
`Arguments/Remarks
`Made in Amendment at
`6-9
`July 10, 2023
`Arguments/Remarks
`Made in Amendment at
`6-11
`
`
`
`1 2
`
`
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`’051 File History
` Aug. 5, 2014, Application
` Nov. 14, 2014, Preliminary
`Amendment
` May 12, 2016, Restriction
`Requirement
` November 3, 2016,
`Response to Restriction
`Requirement
` November 23, 2016, Office
`Action
` May 2, 2017, Response to
`Office Action
`June 6, 2017, Office Action
`
` Aug. 11, 2017 Office
`Action Response
` Aug. 23, 2017 Office
`Action
` September 22, 2017,
`Examiner Interview
`Summary
` Oct. 20, 2017, Examiner
`Interview Summary
` Nov. 6, 2017, Request for
`Continued Examination
` November 24, 2017,
`Examiner Interview
`Summary
`Jun 14, 2018, Notice of
`Allowance
`July 3, 2018, Amendment
`after allowance
`’170 File History
` March 7, 2018 Application
` March 22, 2018
`Preliminary Amendment
` March 8, 2019, Office
`Action
` May 23, 2019, Response to
`Office Action
`July 22, 2019, Office
`Action
`January 21, 2020 Request
`for Continued Examination
`
`
`
`
`
`
`
`
`
`JOINT CLAIM CONSTRUCTION STATEMENT
`
`10
`
`CASE NO. 5:23 CV 04823-EJD
`
`BIO-RAD EX.1003.010
`
`

`

`Case 5:23-cv-06360-EJD Document 65 Filed 06/18/24 Page 11 of 28
`
`Claim Terms
`
`Bio-Rad’s Proposed
`Construction and Evidence in
`Support
`
`
`
`
`
`Plaintiffs’ Proposed
`Construction and Evidence in
`Support2
` May 4, 2020, Notice of
`Allowance
`July 23, 2020 Amendment
`after Notice of Allowance
`July 29, 2020 Response to
`Amendment
`’921 File History
` May 1, 2020, Application
` December 16, 2020,
`Preliminary Amendment
` March 25, 2021,
`Information Disclosure
`Statement (and associated
`references)
` December 28, 2022 Office
`Action
` March 28, 2023 Response
`to Office Action
` May 10, 2023, Office
`Action
`July 10, 2023, Response to
`
`Office Action
` August 10, 2023, Notice of
`Allowance
` October 10, 2023,
`Amendment after Notice of
`Allowance
` October 23, 2023 Notice of
`Allowance
`
`Proposed Construction:
`“each collection of hybridization
`probes specific for a
`polynucleotide analyte”
`
`Proposed Construction:
`Plain and ordinary meaning
`
`Supporting Evidence:
`
`’051 Patent
`2:33-45; 7:12-23; 7:24-37; 7:62-
`8:10; 8:40-57; 9:15-27; 10:26-
`50; 11:13-45; 11:45-63; 12:17-
`28; 33:32-42; 33:43-61; 33:62-
`34:12;
`34:13-35;
`34:36-62;
`34:63-67; 35:1-23; 35:24-45;
`35:46-57; 35:58-36:9; 36:10-21;
`36:22-29; 37:1-15; 39:40-49;
`40:23-40; 40:41-41:6; 41:52-67;
`42:1-22; 42:25-47:30; 52:8-25;
`52:50-56:18; 56:24-37; 56:53-
`
`CASE NO. 5:23 CV 04823-EJD
`
`BIO-RAD EX.1003.011
`
`“each [of said at least 5]
`hybridization probe[s]”
`
`’051 Patent Claim 1.
`’170 Patent Claim 1.
`
`Supporting Evidence:
`
`See e.g., ’051 Patent Claims 1, 2,
`3.
`
`See e.g., ’051 Patent Figs. 1-3, 5,
`7, 8
`
`See e.g., ’051 Patent at:
`2:33-45; 3:35-7:37; 7:49-8:11;
`8:16-18; 8:20-23; 9:15-42;
`10:26-50; 11:13-44; 11:47-
`11
`
`JOINT CLAIM CONSTRUCTION STATEMENT
`
`1 2
`
`
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`

`

`Case 5:23-cv-06360-EJD Document 65 Filed 06/18/24 Page 12 of 28
`
`Claim Terms
`
`Bio-Rad’s Proposed
`Construction and Evidence in
`Support
`25:30; 33:33-37:15; 37:40-55;
`39:41-49; 42:30-47:45; 47:53-
`52:24; 52:31-67:67.
`
`See e.g., ’170 Patent Claim 1.
`
`See e.g., ’170 Patent Figs. 1-3, 5,
`7, 8
`
`See e.g., ’170 Patent at:
`2:35-47; 3:37-7:39; 7:51-8:13;
`8:17-19; 8:21-24; 9:16-44;
`10:26-50; 11:13-45; 11:47-
`23:30; 31:28-35:9; 35:32-47;
`37:33-41; 40:23-44:67; 45:8-
`49:5; 49:16-65:28.
`
`See e.g., ’170 Patent File History
` May 23, 2018 Applicant
`Arguments/Remarks
`Made in Amendment at
`5-8
`January 21, 2019
`Applicant
`Arguments/Remarks
`Made in Amendment at
`5-8
`
`
`
`Plaintiffs’ Proposed
`Construction and Evidence in
`Support2
`69:7; Claims 1-3; Plaintiffs also
`incorporate
`all
`passim
`references to “probes” in the
`patents’ shared specification.
`
`’170 Patent
`Specification passages
`corresponding to ’051 passages
`cited above
`Claims 1, 2, 3, 4, 5, 6, 9, 20
`
`’921 Patent
`Specification passages
`corresponding to ’051 passages
`cited above
`Claims 1, 5, 6, 7, 14, 16, 17, 18
`
`Shared Figures
`
`2-3, 6-7
`
`’051 File History
` Aug. 5, 2014, Application
` Nov. 14, 2014, Preliminary
`Amendment
` May 12, 2016, Restriction
`Requirement
` November 3, 2016,
`Response to Restriction
`Requirement
` November 23, 2016, Office
`Action
` May 2, 2017, Response to
`Office Action
`June 6, 2017, Office Action
`
` Aug. 11, 2017 Office
`Action Response
` Aug. 23, 2017 Office
`Action
` September 22, 2017,
`Examiner Interview
`Summary
` Oct. 20, 2017, Examiner
`Interview Summary
` Nov. 6, 2017, Request for
`Continued Examination
`
`1 2
`
`
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`JOINT CLAIM CONSTRUCTION STATEMENT
`
`12
`
`CASE NO. 5:23 CV 04823-EJD
`
`BIO-RAD EX.1003.012
`
`

`

`Case 5:23-cv-06360-EJD Document 65 Filed 06/18/24 Page 13 of 28
`
`
`
`
`
`
`
`Plaintiffs’ Proposed
`Construction and Evidence in
`Support2
` November 24, 2017,
`Examiner Interview
`Summary
`Jun 14, 2018, Notice of
`Allowance
`July 3, 2018, Amendment
`after allowance
`’170 File History
` March 7, 2018 Application
` March 22, 2018
`Preliminary Amendment
` March 8, 2019, Office
`Action
` May 23, 2019, Response to
`Office Action
`July 22, 2019, Office
`Action
`January 21, 2020 Request
`
`for Continued Examination
` May 4, 2020, Notice of
`Allowance
`July 23, 2020 Amendment
`after Notice of Allowance
`July 29, 2020 Response to
`Amendment
`’921 File History
` May 1, 2020, Application
` December 16, 2020,
`Preliminary Amendment
` March 25, 2021,
`Information Disclosure
`Statement (and associated
`references)
` December 28, 2022 Office
`Action
` March 28, 2023 Response
`to Office Action
` May 10, 2023, Office
`Action
`July 10, 2023, Response to
`
`Office Action
` August 10, 2023, Notice of
`Allowance
` October 10, 2023,
`Amendment after Notice of
`Allowance
` October 23, 2023 Notice of
`Allowance
`
`
`
`
`
`Claim Terms
`
`Bio-Rad’s Proposed
`Construction and Evidence in
`Support
`
`1 2
`
`
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`JOINT CLAIM CONSTRUCTION STATEMENT
`
`13
`
`CASE NO. 5:23 CV 04823-EJD
`
`BIO-RAD EX.1003.013
`
`

`

`Case 5:23-cv-06360-EJD Document 65 Filed 06/18/24 Page 14 of 28
`
`Claim Terms
`
`Bio-Rad’s Proposed
`Construction and Evidence in
`Support
`
`Plaintiffs’ Proposed
`Construction and Evidence in
`Support2
`
`“cumulative intensity
`signal(s)”
`
`’051 Patent Claims 1, 4.
`
`Proposed Construction:
`
`Proposed Construction:
`
`“the signal or collection of
`signals from the probes that
`contact a given analyte”
`
`Supporting Evidence:
`
`Plain and ordinary meaning. To
`the extent a construction is
`necessary, “signal representing
`the total intensity of the light
`emitted by a given probe”
`
`See e.g., ’051 Patent Claims 1, 4.
`
`Supporting Evidence:
`
`See e.g., ’051 Patent Figs. 1-5, 7,
`8
`
`See e.g., ’051 Patent Abstract.
`
`See e.g., ’051 Patent at:
`1:55-2:53; 3:52-6:38; 7:49-8:18;
`8:20-23; 8:58-9:56; 10:15-25;
`11:48-25:30; 29:15-36:67;
`37:18-38:47; 40:9-22; 41:10-31;
`42:30-47:45; 47:53-52:24;
`52:31-67:67.
`
`See e.g., ’051 Patent File History
` May 2, 2017 Applicant
`Arguments/Remarks
`Made in Amendment at
`8-11
` August 11, 2017
`Response After Final
`Action at 16-20
` November 6, 2017
`Applicant
`Arguments/Remarks
`Made in Amendment at
`11-12
`
`’051 Patent
`1:55-60; 2:4-18; 2:52-53; 3:52-
`67; 4:1-65; 5:20-6:38; 7:56-
`8:11; 8:20-23; 9:28-56; 9:34-
`56; 10:15-20; 10:51-11:6;
`11:49-12:3; 14:3-17:60; 18:43-
`19:34; 19:51-25:44; 29:12-
`33:31; 36:10-21; 36:51-67;
`37:16-38:22; 38:23-32; 39:9-
`37; 40:9-41:51; 41:52-67;
`47:30-45; 47:47-51:50; 51:61-
`52:24; 52:8-56: 51; Claims 1, 4;
`Plaintiffs also incorporate all
`passim references to “intensity”
`and “intensities” in the patents’
`shared specification.
`
`’170 Patent
`Specification passages
`corresponding to ’051 passages
`cited above
`Claims 1, 3, 20
`’921 Patent
`Specification passages
`corresponding to ’051 passages
`cited above
`Claims 1, 3
`
`Shared Figures
`
`1-5, 7-8
`
`’051 File History
`
`1 2
`
`
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`JOINT CLAIM CONSTRUCTION STATEMENT
`
`14
`
`CASE NO. 5:23 CV 04823-EJD
`
`BIO-RAD EX.1003.014
`
`

`

`Case 5:23-cv-06360-EJD Document 65 Filed 06/18/24 Page 15 of 28
`
`Plaintiffs’ Proposed
`Construction and Evidence in
`Support2
` Aug. 5, 2014, Application
` Nov. 14, 2014,
`Preliminary Amendment
` May 12, 2016, Restriction
`Requirement
` November 3, 2016,
`Response to Restriction
`Requirement
` November 23, 2016,
`Office Action
` May 2, 2017, Response to
`Office Action
`June 6, 2017, Office
`
`Action
` Aug. 11, 2017 Office
`Action Response
` Aug. 23, 2017 Office
`Action
` September 22, 2017,
`Examiner Interview
`Summary
` Oct. 20, 2017, Examiner
`Interview Summary
` Nov. 6, 2017, Request for
`Continued Examination
` November 24, 2017,
`Examiner Interview
`Summary
`Jun 14, 2018, Notice of
`Allowance
`July 3, 2018, Amendment
`after allowance
`’170 File History
` March 7, 2018 Application
` March 22, 2018
`Preliminary Amendment
` March 8, 2019, Office
`Action
` May 23, 2019, Response to
`Office Action
`July 22, 2019, Office
`Action
`January 21, 2020 Request
`
`for Continued Examination
` May 4, 2020, Notice of
`Allowance
`July 23, 2020 Amendment
`after Notice of Allowance
`July 29, 2020 Response to
`Amendment
`
`
`
`
`
`
`
`
`
`
`
`Claim Terms
`
`Bio-Rad’s Proposed
`Construction and Evidence in
`Support
`
`1 2
`
`
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`JOINT CLAIM CONSTRUCTION STATEMENT
`
`15
`
`CASE NO. 5:23 CV 04823-EJD
`
`BIO-RAD EX.1003.015
`
`

`

`Case 5:23-cv-06360-EJD Document 65 Filed 06/18/24 Page 16 of 28
`
`Claim Terms
`
`Bio-Rad’s Proposed
`Construction and Evidence in
`Support
`
`Plaintiffs’ Proposed
`Construction and Evidence in
`Support2
`’921 File History
` May 1, 2020, Application
` December 16, 2020,
`Preliminary Amendment
` March 25, 2021,
`Information Disclosure
`Statement (and associated
`references)
` December 28, 2022 Office
`Action
` March 28, 2023 Response
`to Office Action
` May 10, 2023, Office
`Action
`July 10, 2023, Response to
`
`Office Action
` August 10, 2023, Notice of
`Allowance
` October 10, 2023,
`Amendment after Notice of
`Allowance
` October 23, 2023 Notice of
`Allowance
`
`“cumulative
`[signal/intensity]
`measurement”
`
`’051 Patent Claim 1.
`’170 Patent Claim 1.
`
`Proposed Construction:
`
`Proposed Construction:
`
`“the signal or collection of
`signals from the probes that
`contact the present analytes”
`
`’051 Patent Claim 1:
`“measurement of the cumulative
`intensity signal(s) in the volume”
`
`Supporting Evidence:
`
`See e.g., ’051 Patent Claim 1.
`
`See e.g., ’051 Patent Figs. 1-5, 7,
`8
`
`See e.g., ’051 Patent Abstract.
`
`See e.g., ’051 Patent at:
`1:55-2:53; 3:52-6:38; 7:49-8:18;
`8:20-23; 8:58-9:56; 10:8-25;
`11:48-25:30; 29:15-36:67;
`37:18-38:47; 40:9-22; 41:10-31;
`42:30-47:45; 47:53-52:24;
`52:31-67:67.
`
`’170 Patent Claim 1:
`“measurement of the cumulative
`intensity of the signal(s) in the
`plurality of droplets”
`
`Supporting Evidence:
`
`’051 Patent
`1:55-60; 2:4-18; 2:52-53; 3:52-
`67; 4:1-65; 5:20-6:38; 7:56-
`8:11; 8:20-23; 9:28-56; 9:34-
`56; 10:15-20; 10:51-11:6;
`11:49-12:3; 14:3-17:60; 18:43-
`19:34; 19:51-25:44; 29:12-
`33:31; 36:10-21; 36:51-67;
`37:16-38:22; 38:23-32; 39:9-
`37; 40:9-41:51; 41:52-67;
`
`JOINT CLAIM CONSTRUCTION STATEMENT
`
`16
`
`CASE NO. 5:23 CV 04823-EJD
`
`BIO-RAD EX.1003.016
`
`1 2
`
`
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`

`

`Case 5:23-cv-06360-EJD Document 65 Filed 06/18/24 Page 17 of 28
`
`Claim Terms
`
`Bio-Rad’s Proposed
`Construction and Evidence in
`Support
`See e.g., ’051 Patent File History
` May 2, 2017 Applicant
`Arguments/Remarks
`Made in Amendment at
`8-11
` August 11, 2017
`Response After Final
`Action at 16-20
` November 6, 2017
`Applicant
`Arguments/Remarks
`Made in Amendment at
`11-12
`
`See e.g., ’170 Patent Claim 1.
`
`See e.g., ’170 Patent Figs. 1-5, 7,
`8.
`
`See e.g., ’170 Patent Abstract.
`
`See e.g., ’170 Patent at:
`1:56-2:55; 3:54-6:40; 7:51-8:19;
`8:21-24; 8:59-9:58; 10:8-25;
`11:47-23:30; 27:11-34:62;
`35:11-36:42; 38:1-15; 39:1-20;
`40:23-44:67; 45:8-49:5; 49:16-
`65:28.
`
`See e.g., ’170 Patent File History
` May 23, 2018 Applicant
`Arguments/Remarks
`Made in Amendment at
`5-8
`January 21, 2019
`Applicant
`Arguments/Remarks
`Made in Amendment at
`5-8
`
`
`
`Plaintiffs’ Proposed
`Construction and Evidence in
`Support2
`47:30-45; 47:47-51:50; 51:61-
`52:24; 52:8-58; 56:18-51;
`Claims 1, 4; Plaintiffs also
`incorporate all passim
`references to “intensity” and
`“intensities” in the patents’
`shared specification.
`’170 Patent
`Specification passages
`corresponding to ’051 passages
`cited above
`Claims 1, 3, 20
`’921 Patent
`Specification passages
`corresponding to ’051 passages
`cited above
`Claims 1, 3
`
`Shared Figures
`Figures 1-8
`’051 File History
` Aug. 5, 2014, Application
` Nov. 14, 2014, Preliminary
`Amendment
` May 12, 2016, Restriction
`Requirement
` November 3, 2016,
`Response to Restriction
`Requirement
` November 23, 2016, Office
`Action
` May 2, 2017, Response to
`Office Action
`June 6, 2017, Office Action
`
` Aug. 11, 2017 Office
`Action Response
` Aug. 23, 2017 Office
`Action
` September 22, 2017,
`Examiner Interview
`Summary
` Oct. 20, 2017, Examiner
`Interview Summary
` Nov. 6, 2017, Request for
`Continued Examination
`
`1 2
`
`
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`JOINT CLAIM CONSTRUCTION STATEMENT
`
`17
`
`CASE NO. 5:23 CV 04823-EJD
`
`BIO-RAD EX.1003.017
`
`

`

`Case 5:23-cv-06360-EJD Document 65 Filed 06/18/24 Page 18 of 28
`
`
`
`
`
`
`
`Plaintiffs’ Proposed
`Construction and Evidence in
`Support2
` November 24, 2017,
`Examiner Interview
`Summary
`Jun 14, 2018, Notice of
`Allowance
`July 3, 2018, Amendment
`after allowance
`’170 File History
` March 7, 2018 Application
` March 22, 2018
`Preliminary Amendment
` March 8, 2019, Office
`Action
` May 23, 2019, Response to
`Office Action
`July 22, 2019, Office
`Action
`January 21, 2020 Request
`
`for Continued Examination
` May 4, 2020, Notice of
`Allowance
`July 23, 2020 Amendment
`after Notice of Allowance
`July 29, 2020 Response to
`Amendment
`’921 File History
` May 1, 2020, Application
` December 16, 2020,
`Preliminary Amendment
` March 25, 2021,
`Information Disclosure
`Statement (and associated
`references)
` December 28, 2022 Office
`Action
` March 28, 2023 Response
`to Office Action
` May 10, 2023, Office
`Action
`July 10, 2023, Response to
`
`Office Action
` August 10, 2023, Notice of
`Allowance
` October 10, 2023,
`Amendment after Notice of
`Allowance
` October 23, 2023 Notice of
`Allowance
`
`
`
`
`
`Claim Terms
`
`Bio-Rad’s Proposed
`Construction and Evidence in
`Support
`
`1 2
`
`
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`JOINT CLAIM CONSTRUCTION STATEMENT
`
`18
`
`CASE NO. 5:23 CV 04823-EJD
`
`BIO-RAD EX.1003.018
`
`

`

`Case 5:23-cv-06360-EJD Document 65 Filed 06/18/24 Page 19 of 28
`
`Claim Terms
`
`“single sample solution
`volume”
`
`’051 Patent Claim 1.
`
`Bio-Rad’s Proposed
`Construction and Evidence in
`Support
`Proposed Construction:
`
`Plaintiffs’ Proposed
`Construction and Evidence in
`Support2
`Proposed Construction:
`
`Non-limiting
`
`Limiting
`
`Supporting Evidence:
`
`Supporting Evidence:
`
`See e.g., ’051 Patent Claim 1.
`See e.g., ’051 Patent Figs. 1-8.
`See e.g., ’051 Patent Abstract.
`See e.g., ’051 Patent a